News and Events

Acute myeloid leukemia. Image credit: iStock

Researchers uncover why a leukemia treatment can cause problems with movement and balance

Ara-C, also known as cytarabine, is the most common chemotherapy to cause cerebellar toxicity. Researchers discovered how the treatment leaves certain neurons with double-strand breaks in their DNA.

Doctor with patient. Image credit: Canva

Clinical trial researching drug therapy for cancers of the female reproductive organs

A clinical trial led by Jung-Min Lee, M.D., Senior Investigator in the Women’s Malignancies Branch, is researching drug therapy for ovarian, endometrial or cervical cancers.

Shioko Kimura, Ph.D., in her CCR lab in 2014.

Celebrating CCR Careers: Shioko Kimura, Ph.D.

Shioko Kimura, Ph.D., is a biochemist who specializes in endocrinology. She studies how certain genes and proteins work in the thyroid gland and the lungs. After almost 40 years at NCI, she has announced her retirement.

Blood from wildtype mice (left) showing blast-like T-ALL cells with characteristic blue nuclear staining; blood from mice in which CHMP5 is deficient in thymocytes (right) showing no evidence of T-ALL cells in the blood.

Protein shown to promote transcription factors that support cancer genes in leukemia

CCR researchers have discovered that the CHMP5 protein promotes transcription factors that initiate and sustain the expression of cancer genes in T-cell acute lymphoblastic leukemia models.

Jim Mitchell in front of a machine and a sign that says X-ray on

Celebrating CCR Careers: James B. Mitchell, Ph.D.

James (Jim) B. Mitchell, Ph.D., is a radiation biologist whose research focuses on evaluation of agents in combination with radiation that either enhance tumor sensitivity or protect normal tissues. After nearly 50 years at the NCI, Mitchell has announced his retirement.

Clinical trial researching T-cell therapy for gastrointestinal cancer

A clinical trial led by Nicholas D. Klemen, M.D., Physician-Scientist Early Investigator in the Surgery Branch, is researching T-cell therapy for gastrointestinal cancer.

In people with VHL disease, HIF protein complexes accumulate and promote tumor growth. By binding to HIF-2α (green portion of the HIF protein complex), belzutifan (purple hexagon) inhibits HIF’s tumor-promoting activity.

Belzutifan works steadily in people with VHL-associated tumors

In a recent clinical trial, belzutifan shows long-lasting benefits for patients with von Hippel-Lindau disease.

Phylogenetic tree of 94 viral strains corresponding to 153 viral peptides that are beneficial virus-related antigens. Colors in the circles indicate different virus classifications at the species (inner circle) and genus (outer circle) level.

Protein found on the common cold virus can activate anti-cancer immune response

Researchers found a viral protein that can activate certain immune cells to produce robust anti-cancer responses against liver cancer.

Doctor speaking with patient. Image credit: Canva

Clinical trial researching radiation for brain cancer

A clinical trial led by Peter Mathen, M.D., Staff Clinician in the Radiation Oncology Branch, is researching a safe schedule for using radiation for adults with glioblastoma.

New Milestones publication now available

Every year, CCR makes remarkable contributions to the understanding, detection, treatment and prevention of cancer. This digital-only issue of our annual publication, Milestones, features 13 of our top scientific advances from the previous year. These discoveries fall everywhere on the spectrum from basic science to clinical research, ranging from a deeper understanding of the gut-liver axis and how bacteria move, to results and stories from three promising clinical trials. Our researchers have developed AI models to predict when tumors will respond to treatments, built scaffolds of biomaterials to assist with drug delivery, investigated how mitochondria function in healthy and diseased liver cells, and more.

Breadcrumb